Y Intercept Hong Kong Ltd Has $374,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Y Intercept Hong Kong Ltd trimmed its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 66.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 35,007 shares of the biopharmaceutical company's stock after selling 68,109 shares during the period. Y Intercept Hong Kong Ltd's holdings in Amicus Therapeutics were worth $374,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $26,000. Hazlett Burt & Watson Inc. grew its position in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 1,569 shares during the last quarter. Blue Trust Inc. grew its position in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $55,000.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company's stock, valued at $9,398,532.40. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 30,401 shares of company stock valued at $339,363. Company insiders own 2.20% of the company's stock.

Analysts Set New Price Targets

FOLD has been the topic of a number of research reports. StockNews.com upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Tuesday, December 10th. JPMorgan Chase & Co. increased their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, November 12th. Jefferies Financial Group began coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a "buy" rating and a $18.00 price target for the company. Bank of America increased their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, October 17th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.88.

Amicus Therapeutics Stock Performance

Shares of FOLD traded down $0.01 during trading hours on Tuesday, reaching $9.89. 1,946,241 shares of the company's stock traded hands, compared to its average volume of 2,719,698. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -29.09 and a beta of 0.60. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57. The business's fifty day simple moving average is $10.51 and its two-hundred day simple moving average is $10.62.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.